Menu
Back to User profile » Dr Yukio Nakamura
Papers published by Dr Yukio Nakamura:
Associations of LRP5 and MTHFR Gene Variants with Osteoarthritis Prevalence in Elderly Women: A Japanese Cohort Survey Randomly Sampled from a Basic Resident Registry
Nakano M, Yui H, Kikugawa S, Tokida R, Sakai N, Kondo N, Endo N, Haro H, Shimodaira H, Suzuki T, Kato H, Takahashi J, Nakamura Y
Therapeutics and Clinical Risk Management 2021, 17:1065-1073
Published Date: 29 September 2021
Short- to Mid-Term Clinical Outcomes of Posterior-Stabilized Cementless Total Knee Arthroplasty with Trabecular Metal Components
Momose T, Nakamura Y, Nakano M, Maeda T, Morioka S, Sobajima A, Nakatsuchi Y, Takahashi J, Nawata M
Therapeutics and Clinical Risk Management 2021, 17:809-816
Published Date: 10 August 2021
Efficacy of denosumab therapy for a 21-year-old woman with Prader-Willi syndrome, osteoporosis and history of fractures: a case report
Uehara M, Nakamura Y, Takahashi J, Suzuki T, Iijima M, Arakawa Y, Ida K, Kosho T, Kato H
Therapeutics and Clinical Risk Management 2019, 15:303-307
Published Date: 25 February 2019
Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis
Suzuki T, Nakamura Y, Kato H
Therapeutics and Clinical Risk Management 2019, 15:15-22
Published Date: 18 December 2018
Efficacy of denosumab therapy for neurofibromatosis type I with osteoporosis and history of fractures: a case report
Uehara M, Nakamura Y, Takahashi J, Kamimura M, Isobe F, Yamaguchi T, Kosho T, Uchiyama S, Suzuki T, Kato H
Therapeutics and Clinical Risk Management 2018, 14:1243-1246
Published Date: 16 July 2018
Adequate nutrition status important for bone mineral density improvement in a patient with anorexia nervosa
Nakamura Y, Kamimura M, Koiwai H, Kato H
Therapeutics and Clinical Risk Management 2018, 14:945-948
Published Date: 18 May 2018
Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis
Uehara M, Nakamura Y, Takahashi J, Suzuki T, Kato H
Therapeutics and Clinical Risk Management 2018, 14:817-822
Published Date: 3 May 2018
Pre-treatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
Kamimura M, Taguchi A, Nakamura Y, Koiwai H, Ikegami S, Uchiyama S, Kato H
Therapeutics and Clinical Risk Management 2018, 14:637-642
Published Date: 3 April 2018
Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment
Nakamura Y, Kamimura M, Morikawa A, Taguchi A, Suzuki T, Kato H
Therapeutics and Clinical Risk Management 2018, 14:543-549
Published Date: 14 March 2018
Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
Suzuki T, Nakamura Y, Kato H
Therapeutics and Clinical Risk Management 2018, 14:453-459
Published Date: 1 March 2018
Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment
Nakamura Y, Suzuki T, Kato H
Therapeutics and Clinical Risk Management 2017, 13:1343-1348
Published Date: 9 October 2017
Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D3 and alters values of parathyroid hormone, pentosidine, and bone metabolic markers
Kamimura M, Uchiyama S, Nakamura Y, Ikegami S, Mukaiyama K, Kato H
Therapeutics and Clinical Risk Management 2017, 13:161-168
Published Date: 13 February 2017
A case series of pregnancy- and lactation-associated osteoporosis and a review of the literature
Nakamura Y, Kamimura M, Ikegami S, Mukaiyama K, Komatsu M, Uchiyama S, Kato H
Therapeutics and Clinical Risk Management 2015, 11:1361-1365
Published Date: 7 September 2015